BioSpace News Archive

XOMA Corporation, the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.

Sensei Biotherapeutics, Inc. reported financial results for the first quarter ended March 31, 2024, and provided corporate updates.

Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease.

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, announced financial results for the first quarter ended March 31, 2024 and provided an update on its business.

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended March 31, 2024, and highlighted recent business updates.

Nvelop Therapeutics to Share the First Preclinical Data from its Novel, Humanized Particle Platform for In Vivo Delivery of Genetic Cargoes at the ASGCT Annual Meeting.

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024.

Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President.

Virios Therapeutics, Inc. today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Lucid Diagnostics Inc. has been subjected to a Class II FDA recall due to two serious device failures reported in a recent publication of one of these studies.